Bearish
Lipocine stock plunges after LPCN 1154 misses phase 3 primary endpoint
Lipocine's stock plummeted after its drug LPCN 1154 failed to meet the primary endpoint in a Phase 3 study aimed at managing preterm labor. This clini...